News Regeneron and Alnylam seek RNAi therapies for NASH Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement.
News Intercept shares dive after FDA safety alert on liver drug Regulator warns of death risk in patients on higher than recommended dose.
News Novo Nordisk board member quits over NASH conflict of intere... Mary Szela has quit to avoid a conflict of interest.
News Genfit encounters trial recruitment problem in hunt for NASH... Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
News Novartis and Allergan to combine drugs in NASH Swiss pharma also aims for new CAR-T therapy indication.
Views & Analysis Novartis muscles into NASH fatty liver disease Company's Eric Hughes on what it takes to be leader in NASH - and what can be learnt from hepatitis C.
News DNA testing can help right racial imbalance in breast cancer Study suggests routine genomic testing could correct well-established disparities in breast cancer survival rates between white and black women.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.